Products with Antileukaemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5824 | Piceatannol |
| Piceatannol has antitumor, antioxidant, and anti-inflammatory activities, it also has the potential to control obesity. Piceatannol inhibits effector T cell functions by suppressing TcR signaling. | |
| BCN5879 | Ganodermanondiol |
| Ganodermanondiol exhibits potent cytoprotective effects on t-BHP-induced hepatotoxicity in human liver-derived HepG2 cells, presumably through Nrf2-mediated antioxidant enzymes and AMPK. It also can significantly inhibit the proliferation of leukemic cancer cells, and it could be one of the antileukemie active constituents of Ganoderma lucidum. Ganodermanondiol shows a strong anticomplement activity against the classical pathway (CP) of the complement system with IC(50) values of 41.7 microM. It shows significant anti-human immunodeficiency virus (anti-HIV)-1 protease activity with IC50 values of 20-90 microM. | |
| BCN6250 | Hispidulin |
| Hispidulin has anti-oxidative, anti-inflammatory, anti-cancer, antiepileptic, neuroprotective, anti-osteoporotic and bone resorption attenuating effects, it targets the VEGF receptor 2-mediated PI3K/Akt/mTOR signaling pathway in endothelial cells, leading to the suppression of pancreatic tumor growth and angiogenesis. Hispidulin can ameliorate high glucose-mediated endothelial dysfunction via inhibiting PKCβII-associated NLRP3 inflammasome activation and NF-κB signaling, it has potential application in the prevention and treatment of diabetic vascular complications. Hispidulin can inhibit platelet aggregation by elevating cAMP levels by a mechanism different from that of theophylline or PGE1. | |
| BCN6264 | Dihydroartemisinin |
| Dihydroartemisinin is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs, recommended as the first-line anti-malarial drug with low toxicity. Dihydroartemisinin has anticancer activity, it inhibited cell proliferation via AKT/GSK3β/cyclinD1/ERK pathway and induced apoptosis is associated with inhibition of Sarco/Endoplasmic reticulum Calcium ATPase activity in colorectal cancer. | |
| BCN6320 | Coptisine |
| Coptisine is an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM, it can consequently prevent neuron loss, reduce amyloid plaque formation, and ameliorate impaired cognition, it could as a potential new class of drugs for AD treatment. Coptisine has cardioprotection, anti- hypercholesterolemia, anti-fungal, anti-osteosarcoma, anti-hepatoma and anti-leukaemia activities, it also has antispasmodic and relaxant activity on a guinea-pig ileum. | |
